Infectious SARS-CoV-2 Particles from Rectal Swab Samples from COVID-19 Patients in Brazil

Viruses. 2023 May 11;15(5):1152. doi: 10.3390/v15051152.

Abstract

The main objective of this study was to investigate the dynamic of SARS-CoV-2 viral excretion in rectal swab (RS), saliva, and nasopharyngeal swab (NS) samples from symptomatic patients and asymptomatic contacts. In addition, in order to evaluate the replication potential of SARS-CoV-2 in the gastrointestinal (GI) tract and the excretion of infectious SARS-CoV-2 from feces, we investigated the presence of subgenomic nucleoprotein gene (N) mRNA (sgN) in RS samples and cytopathic effects in Vero cell culture. A prospective cohort study was performed to collect samples from symptomatic patients and contacts in Rio de Janeiro, Brazil, from May to October 2020. One hundred and seventy-six patients had samples collected at home visits and/or during the follow up, resulting in a total of 1633 RS, saliva, or NS samples. SARS-CoV-2 RNA was detected in 130 (73.9%) patients who had at least one sample that tested positive for SARS-CoV-2. The presence of replicating SARS-CoV-2 in RS samples, measured by the detection of sgN mRNA, was successfully achieved in 19.4% (6/31) of samples, whilst infectious SARS-CoV-2, measured by the generation of cytopathic effects in cell culture, was identified in only one RS sample. Although rare, our results demonstrated the replication capacity of SARS-CoV-2 in the GI tract, and infectious viruses in one RS sample. There is still a gap in the knowledge regarding SARS-CoV-2 fecal-oral transmission. Additional studies are warranted to investigate fecal or wastewater exposure as a risk factor for transmission in human populations.

Keywords: Brazil; SARS-CoV-2; acute gastroenteritis; children; stool samples; young adults.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brazil / epidemiology
  • COVID-19* / diagnosis
  • COVID-19* / epidemiology
  • Communicable Diseases*
  • Humans
  • Prospective Studies
  • RNA, Viral / genetics
  • SARS-CoV-2 / genetics

Substances

  • RNA, Viral

Grants and funding

This work was supported by Programa Inova—Geração de Conhecimento—Enfrentamento da Pandemia e Pós-Pandemia COVID-19 (grant n. VPPCB-005-FIO-20-2-93), Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro, FAPERJ (grant numbers: 202.796/2019—Jovem Cientista do Nosso Estado, TMF; E-26/200.935/2022, E-26/210.149/2020, E-26/211.565/2019, PB; Ministério da Ciência, Tecnologia e Inovação—Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 311562/2021-3, PB); PAEF-2—Oswaldo Cruz Institute, and Ação 21C0, Fiocruz. MCB was a recipient of the CNPq fellowship for Productivity in Technological Development and Innovative (308164/2020-2) and Faperj Programa Cientista do Nosso Estado—2020: CNE2020 (E-26/201.207/2021). This work was also supported by Faperj-E_31/2021—Apoio a projetos científicos e tec. para vacinas e terapias contra a COVID-19—2021. Fumian TM is Research Productivity Fellowship from the Brazilian CNPq.